We are revolutionizing drug discovery with a disruptive, mass spectrometry-powered platform that outperforms structure-based drug design (SBDD) and DNA-encoded library (DEL) approaches. Our platform retains the scalability of traditional methods while overcoming their limitations by directly measuring receptor–ligand interactions using high-resolution mass spectrometry instruments. This enables faster, more accurate, and clinically relevant identification of drug candidates.
Our vision is to transform how new medicines are discovered by building a breakthrough technology platform that uses mass spectrometry to directly study how proteins and drug-like molecules interact. This approach helps us better understand which natural compounds can work as effective treatments and speeds up the process of turning them into real therapies for patients.
Our mission is to pioneer the discovery and delivery of innovative therapeutics for challenging targets and diseases by harnessing our novel technology platform. We are dedicated to pushing the boundaries of what's possible in drug development, focusing on areas where conventional approaches fall short. Through our unique and cutting-edge platform, we aim to unlock new pathways and identify effective treatments, ultimately bringing life-changing medicines to patients suffering from complex and underserved conditions.
Mass spectrometry instruments are reaching a critical point in resolution and sensitivity, making them well-suited to become the leading analytical tools in drug discovery. Mass spectrometry instruments can directly measure molecular interactions with high precision offers a powerful alternative to traditional screening methods.